PMID- 27176479
OWN - NLM
STAT- MEDLINE
DCOM- 20161219
LR  - 20181202
IS  - 1471-2377 (Electronic)
IS  - 1471-2377 (Linking)
VI  - 16
DP  - 2016 May 12
TI  - Neuroimaging basis in the conversion of aMCI patients with APOE-epsilon4 to AD: study 
      protocol of a prospective diagnostic trial.
PG  - 64
LID - 10.1186/s12883-016-0587-2 [doi]
LID - 64
AB  - BACKGROUND: The epsilon4 allele of the Apolipoprotein E gene (APOE-epsilon4) is a potent 
      genetic risk factor for sporadic Alzheimer's disease (AD). Amnestic mild 
      cognitive impairment (aMCI) is an intermediate state between normal cognitive 
      aging and dementia, which is easy to convert to AD dementia. It is an urgent 
      problem in the field of cognitive neuroscience to reveal the conversion of 
      aMCI-epsilon4 to AD. Based on our preliminary work, we will study the neuroimaging 
      features in the special group of aMCI-epsilon4 with multi-modality magnetic resonance 
      imaging (structural MRI, resting state-fMRI and diffusion tensor imaging) 
      longitudinally. METHODS/DESIGN: In this study, 200 right-handed subjects who are 
      diagnosed as aMCI with APOE-epsilon4 will be recruited at the memory clinic of the 
      Neurology Department, XuanWu Hospital, Capital Medical University, Beijing, 
      China. All subjects will undergo the neuroimaging and neuropsychological 
      evaluation at a 1 year-interval for 3 years. The primary outcome measures are 1) 
      Microstructural alterations revealed with multimodal MRI scans including 
      structure MRI (sMRI), resting state functional MRI (rs-fMRI), diffusion tensor 
      imaging (DTI); 2) neuropsychological evaluation, including the World Health 
      Organization-University of California-LosAngeles Auditory Verbal Learning Test 
      (WHO-UCLA AVLT), Addenbrook's cognitive examination-revised (ACE-R), mini-mental 
      state examination (MMSE), Montreal Cognitive Assessment (MoCA), Clinical Dementia 
      Rating scale (CDR). DISCUSSION: This study is to find out the neuroimaging 
      biomarker and the changing laws of the marker during the progress of aMCI-epsilon4 to 
      AD, and the final purpose is to provide scientific evidence for new prevention, 
      diagnosis and treatment of AD. TRIAL REGISTRATION: This study has been registered 
      to ClinicalTrials.gov (NCT02225964, https://www.clinicaltrials.gov/ ) in August 
      24, 2014.
FAU - Chen, Guan-Qun
AU  - Chen GQ
AD  - Department of Neurology, XuanWu Hospital of Capital Medical University, Beijing, 
      100053, China.
FAU - Sheng, Can
AU  - Sheng C
AD  - Department of Neurology, XuanWu Hospital of Capital Medical University, Beijing, 
      100053, China.
FAU - Li, Yu-Xia
AU  - Li YX
AD  - Department of Neurology, XuanWu Hospital of Capital Medical University, Beijing, 
      100053, China.
AD  - Department of Neurology, Tangshan Gongren Hospital, Tangshan, 063000, China.
FAU - Yu, Yang
AU  - Yu Y
AD  - Department of Neurology, XuanWu Hospital of Capital Medical University, Beijing, 
      100053, China.
FAU - Wang, Xiao-Ni
AU  - Wang XN
AD  - Department of Neurology, XuanWu Hospital of Capital Medical University, Beijing, 
      100053, China.
FAU - Sun, Yu
AU  - Sun Y
AD  - Department of Neurology, XuanWu Hospital of Capital Medical University, Beijing, 
      100053, China.
FAU - Li, Hong-Yan
AU  - Li HY
AD  - Department of Neurology, XuanWu Hospital of Capital Medical University, Beijing, 
      100053, China.
AD  - Department of Neurology, Civil Aviation General Hospital, Beijing, 100123, China.
FAU - Li, Xuan-Yu
AU  - Li XY
AD  - Department of Neurology, XuanWu Hospital of Capital Medical University, Beijing, 
      100053, China.
FAU - Xie, Yun-Yan
AU  - Xie YY
AD  - Department of Neurology, XuanWu Hospital of Capital Medical University, Beijing, 
      100053, China.
FAU - Han, Ying
AU  - Han Y
AD  - Department of Neurology, XuanWu Hospital of Capital Medical University, Beijing, 
      100053, China. hanying@xwh.ccmu.edu.cn.
AD  - Center of Alzheimer's Disease, Beijing Institute for Brain Disorders, Beijing, 
      100053, China. hanying@xwh.ccmu.edu.cn.
LA  - eng
SI  - ClinicalTrials.gov/NCT02225964
PT  - Journal Article
DEP - 20160512
PL  - England
TA  - BMC Neurol
JT  - BMC neurology
JID - 100968555
RN  - 0 (Apolipoprotein E4)
RN  - 0 (Biomarkers)
SB  - IM
MH  - Alzheimer Disease/*diagnostic imaging/genetics/psychology
MH  - Apolipoprotein E4/genetics
MH  - Biomarkers
MH  - China
MH  - Cognitive Dysfunction/*diagnostic imaging/genetics/psychology
MH  - Diffusion Tensor Imaging/methods
MH  - Disease Progression
MH  - Follow-Up Studies
MH  - Functional Neuroimaging
MH  - Humans
MH  - Image Processing, Computer-Assisted
MH  - Magnetic Resonance Imaging
MH  - Neuropsychological Tests
MH  - Prospective Studies
PMC - PMC4866435
OTO - NOTNLM
OT  - APOE4 allele
OT  - Alzheimer's disease
OT  - Amnestic mild cognitive impairment
OT  - Longitudinal study
OT  - Multimodality
OT  - Neuroimaging techniques
EDAT- 2016/05/14 06:00
MHDA- 2016/12/20 06:00
PMCR- 2016/05/12
CRDT- 2016/05/14 06:00
PHST- 2016/03/23 00:00 [received]
PHST- 2016/05/05 00:00 [accepted]
PHST- 2016/05/14 06:00 [entrez]
PHST- 2016/05/14 06:00 [pubmed]
PHST- 2016/12/20 06:00 [medline]
PHST- 2016/05/12 00:00 [pmc-release]
AID - 10.1186/s12883-016-0587-2 [pii]
AID - 587 [pii]
AID - 10.1186/s12883-016-0587-2 [doi]
PST - epublish
SO  - BMC Neurol. 2016 May 12;16:64. doi: 10.1186/s12883-016-0587-2.